Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...

Q4 2024 Management View CEO Richard Miller detailed the progress of soquelitinib, emphasizing its potential as a first-in-class oral therapy for immune diseases and cancers. He highlighted the 39% ...

(RTTNews) - Corvus Pharmaceuticals (CRVS), Wednesday announced the initiation of a Phase 2 clinical trial for soquelitinib, an investigational drug, in partnership with the National Institute of ...

Corvus Pharmaceuticals (CRVS) announced that additional data from the Company’s Phase 1/1b clinical trial of soquelitinib for the treatment of ...

Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...

Corvus Pharmaceuticals reported positive Phase 1/1b trial data for soquelitinib in T cell lymphoma, showing significant anti-tumor activity. Corvus Pharmaceuticals, Inc. announced new findings ...

“The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of ...

Dr. Rao previously presented preclinical data supporting the potential of soquelitinib in patients with ALPS. Other trial sites include Children’s Hospital of Philadelphia and Texas Children’s ...

Reports as of December 31, Corvus had cash, cash equivalents and marketable securities of $52.M as compared to $27.1M as of December 31, 2023.

SOUTH SAN FRANCISCO – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company with a market capitalization of $284 million, today shared additional data from its Phase ...

SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...